From Center for Health Outcomes Research, MEDTAP Institute, Bethesda, MD (Drs. Revicki and Kimel, and Ms. Beusterien); GlaxoSmithKline Research and Development, Research Triangle Park, NC (Drs. Kwong, Varner, Ames, and Mahajan); and Headache Care Center, Springfield, MO (Dr. Cady).
Validation of the Revised Patient Perception of Migraine Questionnaire: Measuring Satisfaction With Acute Migraine Treatment
Version of Record online: 21 FEB 2006
Headache: The Journal of Head and Face Pain
Volume 46, Issue 2, pages 240–252, February 2006
How to Cite
Revicki, D. A., Kimel, M., Beusterien, K., Kwong, J. W., Varner, J. A., Ames, M. H., Mahajan, S. and Cady, R. K. (2006), Validation of the Revised Patient Perception of Migraine Questionnaire: Measuring Satisfaction With Acute Migraine Treatment. Headache: The Journal of Head and Face Pain, 46: 240–252. doi: 10.1111/j.1526-4610.2006.00289.x
- Issue online: 21 FEB 2006
- Version of Record online: 21 FEB 2006
- Accepted for publication July 27, 2005.
- treatment satisfaction;
Objective.—To evaluate the psychometric properties of the revised Patient Perception of Migraine Questionnaire (PPMQ-R), which measures satisfaction with migraine treatment.
Background.—The original version of the PPMQ was developed prior to the introduction of newer migraine treatments, which may have attributes that influence treatment satisfaction.
Methods.—Literature review, patient focus groups, and one-on-one patient interviews guided revisions to the original PPMQ. The revised questionnaire was tested in 200 migraine patients visiting neurologists and primary care clinics. At baseline, all subjects completed the PPMQ-R, a migraine-specific quality-of-life measure, and a migraine experience questionnaire; and 125 subjects completed assessments 24 hours after each migraine attack and within 30 days post-baseline. Factor analysis was performed to inform the development of a scoring algorithm, and reliability, validity, and responsiveness of the PPMQ-R were evaluated.
Results.—Factor analyses confirmed that the revised questionnaire has five domains measuring satisfaction with efficacy, functionality, ease of use, medication cost, and bothersomeness of medication side effects. A total score can be created by taking the average of efficacy, functionality, and ease of use scores. The PPMQ-R scale scores and Total score demonstrated internal consistency reliability (Cronbach's α: 0.80 to 0.98) and test–retest reliability (intra-class correlation coefficient: 0.79 to 0.91). Except for the Cost domain, the PPMQ-R scores discriminated among migraine pain severity levels (all P < .05) and levels of impairment in ability to work and perform usual activities (all P < .05). Except for the Ease of Use and Cost domains, mean PPMQ-R scores were significantly higher among patients with no change in treatment and whose pain improved between two consecutive migraine attacks (all P < .01).
Conclusion.—The PPMQ-R is a reliable and valid measure of patient satisfaction with acute migraine treatment in women with frequent migraine attacks.